Zmynd8-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Zmynd8-KO 基因敲除小鼠

产品编号

S-KO-06216

品系全称

C57BL/6JCya-Zmynd8em1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-228880-Zmynd8-B6J-VA

品系状态

使用本品系发表的文献需注明: Zmynd8-KO 基因敲除小鼠 mice (Strain S-KO-06216) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
zinc finger, MYND-type containing 8
基因别称
1110013E22Rik,2010005I16Rik,3632413B07Rik,Prkcbp1,RACK7
染色体号
Chr 2 (Mouse)
转录本 ID
NCBI: NM_001291158 | Ensembl: ENSMUST00000109269
修饰方式
全身性基因敲除
靶向范围
Exon 5~12
敲除长度
~18.0 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:1918025Mice homozygous for a conditional allele activated in mammary tissue exhibit reduced mammary tumors and abolished lung metastasis in a transgenic breast cancer model.
ZMYND8,也称为Zinc finger MYND-type containing 8,是一种多功能的蛋白质,在细胞内具有多种生物学功能。ZMYND8属于MYND结构域家族的锌指蛋白,MYND结构域是一种包含三个锌指的结构域,与染色质重塑、转录调控和信号转导等功能密切相关。ZMYND8含有多个结构域,包括PWWP结构域、MYND结构域、BRD4结合域等,使其能够与多种蛋白质相互作用,参与多种生物学过程。ZMYND8在多种细胞类型中广泛表达,包括乳腺干细胞、巨噬细胞、急性髓系白血病细胞、神经元细胞、肠干细胞和肝癌细胞等。ZMYND8在细胞内定位包括细胞核和细胞质,其功能涉及染色质重塑、转录调控、细胞分化和信号转导等。

ZMYND8在乳腺癌干细胞中表达上调,并通过激活NRF2保护乳腺癌干细胞免受氧化应激和铁死亡的损伤。ZMYND8通过沉默KEAP1增加NRF2蛋白的稳定性,同时与NRF2相互作用,增强抗氧化基因的转录,从而抑制ROS和铁死亡,促进乳腺癌干细胞的扩增和肿瘤的起始[1]。此外,ZMYND8在巨噬细胞极化过程中,通过与NF-κB/p65形成液体凝聚体,沉默潜在的超级增强子,限制巨噬细胞介导的炎症反应[2]。ZMYND8还在急性髓系白血病细胞中,通过直接激活IRF8,与MYC原癌基因协同作用,促进AML的增殖和白血病的发生[3]。在神经元细胞中,ZMYND8通过抑制MAPT213长链非编码RNA(LncRNA)的转录,促进神经元的分化[4]。ZMYND8还在YAP高表达的肠癌中,通过调节甲羟戊酸途径,赋予肠癌细胞代谢脆弱性,限制肠干细胞的自我更新和肠癌的发生[5]。ZMYND8还能够识别双组蛋白修饰H3K4me1-H3K14ac,与H3K4去甲基化酶JARID1D相互作用,抑制转移相关基因的表达,发挥抗转移的作用[6]。ZMYND8基因的突变导致一种新的常染色体显性遗传性神经发育障碍,伴有心血管、眼科和轻微骨骼异常[7]。ZMYND8在肝细胞癌中表达上调,通过促进HK2介导的糖酵解,促进肝癌细胞的生长和转移[8]。ZMYND8在肝细胞癌中的高表达与不良的临床病理特征和预后相关,其mRNA的过表达可以作为预测肝细胞癌早期复发和短复发无病生存期的独立预后因子[9]。ZMYND8在突变型异柠檬酸脱氢酶1(mIDH1)胶质瘤中表达下调,抑制ZMYND8的表达能够增加mIDH1胶质瘤细胞对放疗的敏感性,表明ZMYND8在维持基因组完整性和修复放疗诱导的DNA损伤中发挥作用[10]。

综上所述,ZMYND8是一种多功能的蛋白质,在细胞内具有多种生物学功能。ZMYND8通过参与染色质重塑、转录调控、细胞分化和信号转导等过程,在乳腺癌、巨噬细胞、急性髓系白血病、神经元、肠干细胞、肝癌和胶质瘤等多种细胞类型中发挥重要作用。ZMYND8的研究有助于深入理解染色质重塑、转录调控和信号转导的生物学功能和疾病发生机制,为疾病的治疗和预防提供新的思路和策略。

参考文献:
1. Luo, Maowu, Bao, Lei, Xue, Yuanyuan, Wang, Yingfei, Luo, Weibo. 2024. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. In The Journal of clinical investigation, 134, . doi:10.1172/JCI171166. https://pubmed.ncbi.nlm.nih.gov/38488001/
2. Jia, Pan, Li, Xiang, Wang, Xuelei, Qin, Jun, Lu, Wei. 2021. ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization. In Nature communications, 12, 6535. doi:10.1038/s41467-021-26864-x. https://pubmed.ncbi.nlm.nih.gov/34764296/
3. Cao, Zhendong, Budinich, Krista A, Huang, Hua, Berger, Shelley L, Shi, Junwei. 2021. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. In Molecular cell, 81, 3604-3622.e10. doi:10.1016/j.molcel.2021.07.018. https://pubmed.ncbi.nlm.nih.gov/34358447/
4. Adhikary, Santanu, Singh, Vipin, Choudhari, Ramesh, Gadad, Shrikanth S, Das, Chandrima. 2022. ZMYND8 suppresses MAPT213 LncRNA transcription to promote neuronal differentiation. In Cell death & disease, 13, 766. doi:10.1038/s41419-022-05212-x. https://pubmed.ncbi.nlm.nih.gov/36064715/
5. Pan, Qiang, Zhong, Shanshan, Wang, Hanling, Xiao, Yichuan, Qin, Jun. 2021. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. In Molecular cell, 81, 2736-2751.e8. doi:10.1016/j.molcel.2021.04.009. https://pubmed.ncbi.nlm.nih.gov/33932349/
6. Li, Na, Li, Yuanyuan, Lv, Jie, Li, Haitao, Lee, Min Gyu. 2016. ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes. In Molecular cell, 63, 470-84. doi:10.1016/j.molcel.2016.06.035. https://pubmed.ncbi.nlm.nih.gov/27477906/
7. Dias, Kerith-Rae, Carlston, Colleen M, Blok, Laura E R, Harvey, Robert J, Roscioli, Tony. 2022. De Novo ZMYND8 variants result in an autosomal dominant neurodevelopmental disorder with cardiac malformations. In Genetics in medicine : official journal of the American College of Medical Genetics, 24, 1952-1966. doi:10.1016/j.gim.2022.06.001. https://pubmed.ncbi.nlm.nih.gov/35916866/
8. Dou, Changwei, Mo, Huanye, Chen, Tianxiang, Guo, Cheng, Zhang, Chengwu. 2021. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis. In Pathology, research and practice, 219, 153345. doi:10.1016/j.prp.2021.153345. https://pubmed.ncbi.nlm.nih.gov/33517164/
9. Choi, Sangjoon, Lee, Keun-Woo, Koh, Hyun Hee, Park, Cheol-Keun, Ha, Sang Yun. 2021. Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. In Journal of cancer research and clinical oncology, 147, 3517-3534. doi:10.1007/s00432-021-03768-3. https://pubmed.ncbi.nlm.nih.gov/34462784/
10. Carney, Stephen V, Banerjee, Kaushik, Mujeeb, Anzar, Lowenstein, Pedro R, Castro, Maria G. . Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. In Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 1763-1782. doi:10.1158/1078-0432.CCR-22-1896. https://pubmed.ncbi.nlm.nih.gov/36692427/